{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:53:09Z","timestamp":1787237589496,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Commission of Hunan Provincial","award":["202113012480"],"award-info":[{"award-number":["202113012480"]}]},{"name":"International Research Center for Precision Medicine, Transformative Technology, and Software Services, Hunan, China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91356-7","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:25:42Z","timestamp":1740133542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A preliminary exploration of liver microsomes and PBPK to uncover the impact of CYP3A4\/5 and CYP2C19 on tacrolimus and voriconazole drug-drug interactions"],"prefix":"10.1038","volume":"15","author":[{"given":"Yi-Chang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Lin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Jing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Kui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Xiong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"91356_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac927","author":"DZP Friedman","year":"2022","unstructured":"Friedman, D. Z. P., Johnson, B., Beam, E., Kremers, W. & Vergidis, P. Risk factors and outcomes of invasive aspergillosis in kidney transplant recipients: A Case-Control study of USRDS data. Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am. https:\/\/doi.org\/10.1093\/cid\/ciac927 (2022).","journal-title":"Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am."},{"key":"91356_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.riam.2018.05.002","volume":"35","author":"JT Silva","year":"2018","unstructured":"Silva, J. T., Torre-Cisneros, J. & Aguado, J. M. [Invasive aspergillosis in solid organ transplantation]. Revista Iberoamericana De Micologia. 35, 206\u2013209. https:\/\/doi.org\/10.1016\/j.riam.2018.05.002 (2018).","journal-title":"Revista Iberoamericana De Micologia"},{"key":"91356_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-05958-3","author":"D Neofytos","year":"2021","unstructured":"Neofytos, D. et al. Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response. BMC Infect. Dis. https:\/\/doi.org\/10.1186\/s12879-021-05958-3 (2021).","journal-title":"BMC Infect. Dis."},{"key":"91356_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.5114\/kitp.2016.61057","volume":"13","author":"T Urbanowicz","year":"2016","unstructured":"Urbanowicz, T. et al. Invasive aspergillosis successfully treated by combined antifungal therapy and immunosuppressive monotherapy two months following heart transplantation. Kardiochirurgia I Torakochirurgia Polska = Pol. J. cardio-thoracic Surg. 13, 164\u2013168. https:\/\/doi.org\/10.5114\/kitp.2016.61057 (2016).","journal-title":"Kardiochirurgia I Torakochirurgia Polska = Pol. J. cardio-thoracic Surg."},{"key":"91356_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/ftd.0000000000000361","volume":"39","author":"H Billing","year":"2017","unstructured":"Billing, H. et al. Single-Nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients: A Pharmacogenetic substudy of the TWIST trial. Ther. Drug Monit. 39, 21\u201328. https:\/\/doi.org\/10.1097\/ftd.0000000000000361 (2017).","journal-title":"Ther. Drug Monit."},{"key":"91356_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/phar.1970","volume":"37","author":"AQ Maldonado","year":"2017","unstructured":"Maldonado, A. Q., Asempa, T., Hudson, S. & Rebellato, L. M. Prevalence of CYP3A5 genomic variances and their impact on tacrolimus dosing requirements among kidney transplant recipients in Eastern North Carolina. Pharmacotherapy 37, 1081\u20131088. https:\/\/doi.org\/10.1002\/phar.1970 (2017).","journal-title":"Pharmacotherapy"},{"key":"91356_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.arcmed.2012.05.005","volume":"43","author":"P Garc\u00eda-Roca","year":"2012","unstructured":"Garc\u00eda-Roca, P. et al. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. Arch. Med. Res. 43, 283\u2013287. https:\/\/doi.org\/10.1016\/j.arcmed.2012.05.005 (2012).","journal-title":"Arch. Med. Res."},{"key":"91356_CR8","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3892\/ijmm.2011.794","volume":"28","author":"A Provenzani","year":"2011","unstructured":"Provenzani, A. et al. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int. J. Mol. Med. 28, 1093\u20131102. https:\/\/doi.org\/10.3892\/ijmm.2011.794 (2011).","journal-title":"Int. J. Mol. Med."},{"key":"91356_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106405","author":"ZR Li","year":"2023","unstructured":"Li, Z. R. et al. Individual dose recommendations for drug interaction between tacrolimus and voriconazole in adult liver transplant recipients: A semiphysiologically based population Pharmacokinetic modeling approach. Eur. J. Pharm. Sciences: Official J. Eur. Federation Pharm. Sci. https:\/\/doi.org\/10.1016\/j.ejps.2023.106405 (2023).","journal-title":"Eur. J. Pharm. Sciences: Official J. Eur. Federation Pharm. Sci."},{"key":"91356_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-2710.2009.01061.x","volume":"35","author":"A Thomas","year":"2010","unstructured":"Thomas, A. et al. Clinical outcomes of lung-transplant recipients treated by voriconazole and Caspofungin combination in aspergillosis. J. Clin. Pharm. Ther. 35, 49\u201353. https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01061.x (2010).","journal-title":"J. Clin. Pharm. Ther."},{"key":"91356_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/8755122519846169","volume":"35","author":"JJ Chheda","year":"2019","unstructured":"Chheda, J. J., Tarleton, A. & Eidem, J. H. Targeted Aspergillus prophylaxis with voriconazole in heart transplant patients: A focus on the interaction with tacrolimus. J. Pharm. Technology: jPT : Official Publication Association Pharm. Technicians. 35, 164\u2013171. https:\/\/doi.org\/10.1177\/8755122519846169 (2019).","journal-title":"J. Pharm. Technology: jPT : Official Publication Association Pharm. Technicians"},{"key":"91356_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12751","author":"AH Groll","year":"2017","unstructured":"Groll, A. H. et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl. Infect. disease: official J. Transplantation Soc. https:\/\/doi.org\/10.1111\/tid.12751 (2017).","journal-title":"Transpl. Infect. disease: official J. Transplantation Soc."},{"key":"91356_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00044011-200929070-00006","volume":"29","author":"EM Billaud","year":"2009","unstructured":"Billaud, E. M. et al. Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and Azole antifungals in a renal transplant patient. Clin. Drug Investig. 29, 481\u2013486. https:\/\/doi.org\/10.2165\/00044011-200929070-00006 (2009).","journal-title":"Clin. Drug Investig."},{"key":"91356_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/cts.12499","volume":"11","author":"N Zhang","year":"2018","unstructured":"Zhang, N. et al. Role of CYP3A in oral contraceptives clearance. Clin. Transl. Sci. 11, 251\u2013260. https:\/\/doi.org\/10.1111\/cts.12499 (2018).","journal-title":"Clin. Transl. Sci."},{"key":"91356_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/138920008784220664","volume":"9","author":"SF Zhou","year":"2008","unstructured":"Zhou, S. F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 9, 310\u2013322. https:\/\/doi.org\/10.2174\/138920008784220664 (2008).","journal-title":"Curr. Drug Metab."},{"key":"91356_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122739","author":"YC Zhao","year":"2022","unstructured":"Zhao, Y. C. et al. The Effect of Voriconazole on Tacrolimus in Kidney Transplantation Recipients: A Real-World Study. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics14122739 (2022).","journal-title":"Pharmaceutics"},{"key":"91356_CR17","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-4124","author":"X Chen","year":"2021","unstructured":"Chen, X. et al. Effects of voriconazole on population pharmacokinetics and optimization of the initial dose of tacrolimus in children with chronic granulomatous disease undergoing hematopoietic stem cell transplantation. Annals Translational Med. https:\/\/doi.org\/10.21037\/atm-21-4124 (2021).","journal-title":"Annals Translational Med."},{"key":"91356_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/fpc.0000000000000494","volume":"33","author":"N Rao","year":"2023","unstructured":"Rao, N. et al. Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation. Pharmacogenet. Genomics. 33, 59\u201365. https:\/\/doi.org\/10.1097\/fpc.0000000000000494 (2023).","journal-title":"Pharmacogenet. Genomics"},{"key":"91356_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-024-00323-4","author":"A Abderahmene","year":"2024","unstructured":"Abderahmene, A. et al. The pharmacogenetics of tacrolimus in renal transplant patients: association with tremors, new-onset diabetes and other clinical events. Pharmacogenomics J. https:\/\/doi.org\/10.1038\/s41397-024-00323-4 (2024).","journal-title":"Pharmacogenomics J."},{"key":"91356_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.110906","author":"S Huang","year":"2024","unstructured":"Huang, S. et al. Pharmacokinetic interactions between tacrolimus and Wuzhi capsule in liver transplant recipients: Genetic polymorphisms affect the drug interaction. Chemico-Biol. Interact. https:\/\/doi.org\/10.1016\/j.cbi.2024.110906 (2024).","journal-title":"Chemico-Biol. Interact."},{"key":"91356_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040789","author":"S Bettonte","year":"2022","unstructured":"Bettonte, S., Berton, M. & Marzolini, C. Magnitude of Drug-Drug Interactions in Special Populations. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics14040789 (2022).","journal-title":"Pharmaceutics"},{"key":"91356_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.15235","author":"ZH Tu","year":"2024","unstructured":"Tu, Z. H., Pierce, B. J., Pasley, T., Hutchins, A. & Huang, H. Immune outcomes of lung transplant recipients with different cytochrome P450 3A5 phenotypes after discontinuation of voriconazole antifungal prophylaxis. Clin. Transplant. https:\/\/doi.org\/10.1111\/ctr.15235 (2024).","journal-title":"Clin. Transplant."},{"key":"91356_CR23","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/jcph.605","volume":"56","author":"CK Imamura","year":"2016","unstructured":"Imamura, C. K., Furihata, K., Okamoto, S. & Tanigawara, Y. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. J. Clin. Pharmacol. 56, 408\u2013413. https:\/\/doi.org\/10.1002\/jcph.605 (2016).","journal-title":"J. Clin. Pharmacol."},{"key":"91356_CR24","doi-asserted-by":"publisher","first-page":"708299","DOI":"10.3389\/fphar.2021.708299","volume":"12","author":"K Abouir","year":"2021","unstructured":"Abouir, K., Samer, C. F., Gloor, Y., Desmeules, J. A. & Daali, Y. Reviewing data integrated for PBPK model development to predict metabolic Drug-Drug interactions: shifting perspectives and emerging trends. Front. Pharmacol. 12, 708299. https:\/\/doi.org\/10.3389\/fphar.2021.708299 (2021).","journal-title":"Front. Pharmacol."},{"key":"91356_CR25","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3390\/pharmaceutics15061586","volume":"15","author":"L Marques","year":"2023","unstructured":"Marques, L. & Vale, N. Prediction of CYP-Mediated drug interaction using physiologically based Pharmacokinetic modeling: A case study of salbutamol and fluvoxamine. Pharmaceutics 15, 1586 (2023).","journal-title":"Pharmaceutics"},{"key":"91356_CR26","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1021\/acs.molpharmaceut.8b00129","volume":"15","author":"J Yadav","year":"2018","unstructured":"Yadav, J., Korzekwa, K. & Nagar, S. Improved predictions of drug\u2013drug interactions mediated by Time-Dependent Inhibition of CYP3A. Mol. Pharm. 15, 1979\u20131995. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00129 (2018).","journal-title":"Mol. Pharm."},{"key":"91356_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/biom14010099","volume":"14","author":"J Lee","year":"2024","unstructured":"Lee, J., Beers, J. L., Geffert, R. M. & Jackson, K. D. A review of CYP-Mediated drug interactions: mechanisms and in vitro drug-Drug interaction assessment. Biomolecules 14, 99 (2024).","journal-title":"Biomolecules"},{"key":"91356_CR28","unstructured":"https:\/\/ngdc.cncb.ac.cn\/databasecommons\/database\/id\/208"},{"key":"91356_CR29","doi-asserted-by":"publisher","first-page":"D1200","DOI":"10.1093\/nar\/gkab880","volume":"50","author":"G Xiong","year":"2022","unstructured":"Xiong, G. et al. DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. Nucleic Acids Res. 50, D1200\u2013d1207. https:\/\/doi.org\/10.1093\/nar\/gkab880 (2022).","journal-title":"Nucleic Acids Res."},{"key":"91356_CR30","doi-asserted-by":"publisher","first-page":"W5","DOI":"10.1093\/nar\/gkab255","volume":"49","author":"G Xiong","year":"2021","unstructured":"Xiong, G. et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 49, W5\u2013w14. https:\/\/doi.org\/10.1093\/nar\/gkab255 (2021).","journal-title":"Nucleic Acids Res."},{"key":"91356_CR31","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1111\/ajt.14232","volume":"17","author":"T Vanhove","year":"2017","unstructured":"Vanhove, T. et al. Determinants of the magnitude of interaction between tacrolimus and Voriconazole\/Posaconazole in solid organ recipients. Am. J. Transplantation: Official J. Am. Soc. Transplantation Am. Soc. Transpl. Surg. 17, 2372\u20132380. https:\/\/doi.org\/10.1111\/ajt.14232 (2017).","journal-title":"Am. J. Transplantation: Official J. Am. Soc. Transplantation Am. Soc. Transpl. Surg."},{"key":"91356_CR32","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/ndt\/gfh593","volume":"20","author":"M Tintillier","year":"2005","unstructured":"Tintillier, M., Kirch, L., Goffin, E., Cuvelier, C. & Pochet, J. M. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol. dialysis Transplantation: Official Publication Eur. Dialysis Transpl. Association - Eur. Ren. Association. 20, 664\u2013665. https:\/\/doi.org\/10.1093\/ndt\/gfh593 (2005).","journal-title":"Nephrol. dialysis Transplantation: Official Publication Eur. Dialysis Transpl. Association - Eur. Ren. Association"},{"key":"91356_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03350-8","author":"G Th\u00f6lking","year":"2022","unstructured":"Th\u00f6lking, G., Jehn, U. & Reuter, S. Interactions with the CYP3A inhibitor voriconazole differ between extended-LCP- and immediate-release tacrolimus formulations. Int. J. Hematol. https:\/\/doi.org\/10.1007\/s12185-022-03350-8 (2022).","journal-title":"Int. J. Hematol."},{"key":"91356_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/bdd.2109","volume":"39","author":"N Watanabe","year":"2018","unstructured":"Watanabe, N. et al. The possible clinical impact of Risperidone on P-glycoprotein-mediated transport of tacrolimus: A case report and in vitro study. Biopharm. Drug Dispos. 39, 30\u201337. https:\/\/doi.org\/10.1002\/bdd.2109 (2018).","journal-title":"Biopharm. Drug Dispos."},{"key":"91356_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/00498254.2011.631224","volume":"42","author":"S Zhang","year":"2012","unstructured":"Zhang, S., Pillai, V. C., Mada, S. R., Strom, S. & Venkataramanan, R. Effect of voriconazole and other Azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica; Fate Foreign Compd. Biol. Syst. 42, 409\u2013416. https:\/\/doi.org\/10.3109\/00498254.2011.631224 (2012).","journal-title":"Xenobiotica; Fate Foreign Compd. Biol. Syst."},{"key":"91356_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1021\/acs.molpharmaceut.8b01043","volume":"16","author":"K Xiao","year":"2019","unstructured":"Xiao, K. et al. CYP3A4\/5 activity probed with testosterone and Midazolam: correlation between two substrates at the microsomal and enzyme levels. Mol. Pharm. 16, 382\u2013392. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b01043 (2019).","journal-title":"Mol. Pharm."},{"key":"91356_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1211\/0022357991772600","volume":"51","author":"F Higashikawa","year":"2010","unstructured":"Higashikawa, F., Murakami, T., Kaneda, T. & Takano, M. In-vivo and In-vitro metabolic clearance of Midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats. J. Pharm. Pharmacol. 51, 405\u2013410. https:\/\/doi.org\/10.1211\/0022357991772600 (2010).","journal-title":"J. Pharm. Pharmacol."},{"key":"91356_CR38","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1124\/dmd.31.7.938","volume":"31","author":"KC Patki","year":"2003","unstructured":"Patki, K. C., Moltke, V., Greenblatt, D. J. & L. L. & In vitro metabolism of Midazolam, Triazolam, Nifedipine, and testosterone by human liver microsomes and Recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab. Dispos. 31, 938\u2013944. https:\/\/doi.org\/10.1124\/dmd.31.7.938 (2003).","journal-title":"Drug Metab. Dispos."},{"key":"91356_CR39","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/10600280231197399","volume":"58","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. CYP3A5 Genotype-Dependent Drug-Drug interaction between tacrolimus and voriconazole in Chinese kidney transplant patients. Ann. Pharmacother. 58, 605\u2013613. https:\/\/doi.org\/10.1177\/10600280231197399 (2024).","journal-title":"Ann. Pharmacother"},{"key":"91356_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1365-2710.2009.01070.x","volume":"35","author":"D Capone","year":"2010","unstructured":"Capone, D. et al. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J. Clin. Pharm. Ther. 35, 121\u2013124. https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01070.x (2010).","journal-title":"J. Clin. Pharm. Ther."},{"key":"91356_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1208\/s12248-012-9446-2","volume":"15","author":"HM Jones","year":"2013","unstructured":"Jones, H. M., Mayawala, K. & Poulin, P. Dose selection based on physiologically based Pharmacokinetic (PBPK) approaches. AAPS J. 15, 377\u2013387. https:\/\/doi.org\/10.1208\/s12248-012-9446-2 (2013).","journal-title":"AAPS J."},{"key":"91356_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/17425255.2019.1558205","volume":"15","author":"A Smits","year":"2019","unstructured":"Smits, A., De Cock, P., Vermeulen, A. & Allegaert, K. Physiologically based Pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute. Expert Opin. Drug Metab. Toxicol. 15, 25\u201334. https:\/\/doi.org\/10.1080\/17425255.2019.1558205 (2019).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"91356_CR43","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","volume":"6","author":"X Zhuang","year":"2016","unstructured":"Zhuang, X. & Lu, C. PBPK modeling and simulation in drug research and development. Acta Pharm. Sin B. 6, 430\u2013440. https:\/\/doi.org\/10.1016\/j.apsb.2016.04.004 (2016).","journal-title":"Acta Pharm. Sin B"},{"key":"91356_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/cpt.905","volume":"104","author":"W Zhou","year":"2018","unstructured":"Zhou, W. et al. Predictive performance of physiologically based Pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin. Pharmacol. Ther. 104, 188\u2013200. https:\/\/doi.org\/10.1002\/cpt.905 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"91356_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00207-21","author":"X Tian","year":"2021","unstructured":"Tian, X. et al. Impact of CYP2C19 phenotype and Drug-Drug interactions on voriconazole concentration in pediatric patients. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00207-21 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"91356_CR46","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1111\/bcp.15385","volume":"88","author":"X Huang","year":"2022","unstructured":"Huang, X. et al. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients. Br. J. Clin. Pharmacol. 88, 4515\u20134525. https:\/\/doi.org\/10.1111\/bcp.15385 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"91356_CR47","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.3390\/pharmaceutics15112580","volume":"15","author":"L Pei","year":"2023","unstructured":"Pei, L. et al. A physiologically based Pharmacokinetic approach to recommend an individual dose of tacrolimus in adult heart transplant recipients. Pharmaceutics 15, 2580 (2023).","journal-title":"Pharmaceutics"},{"key":"91356_CR48","doi-asserted-by":"publisher","first-page":"116475","DOI":"10.1016\/j.taap.2023.116475","volume":"466","author":"F Gong","year":"2023","unstructured":"Gong, F. et al. Physiologically-based Pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles. Toxicol. Appl. Pharmacol. 466, 116475. https:\/\/doi.org\/10.1016\/j.taap.2023.116475 (2023).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"91356_CR49","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/psp4.12946","volume":"12","author":"HLH Loer","year":"2023","unstructured":"Loer, H. L. H. et al. Physiologically based Pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions. CPT Pharmacometrics Syst. Pharmacol. 12, 724\u2013738. https:\/\/doi.org\/10.1002\/psp4.12946 (2023).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"91356_CR50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/bcp.12234","volume":"79","author":"N Tsamandouras","year":"2015","unstructured":"Tsamandouras, N., Rostami-Hodjegan, A. & Aarons, L. Combining the \u2018bottom up\u2019 and \u2018top down\u2019 approaches in Pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br. J. Clin. Pharmacol. 79, 48\u201355. https:\/\/doi.org\/10.1111\/bcp.12234 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"91356_CR51","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1124\/dmd.111.043018","volume":"40","author":"R Amundsen","year":"2012","unstructured":"Amundsen, R., \u00c5sberg, A., Ohm, I. K. & Christensen, H. Cyclosporine A- and Tacrolimus-Mediated inhibition of CYP3A4 and CYP3A5 in vitro. Drug Metab. Dispos. 40, 655\u2013661. https:\/\/doi.org\/10.1124\/dmd.111.043018 (2012).","journal-title":"Drug Metab. Dispos."},{"key":"91356_CR52","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.3390\/ijms23094485","volume":"23","author":"Q He","year":"2022","unstructured":"He, Q. et al. Examination of the impact of CYP3A4\/5 on Drug\u2013Drug interaction between schizandrol A\/Schizandrol B and tacrolimus (FK-506): A physiologically based Pharmacokinetic modeling approach. Int. J. Mol. Sci. 23, 4485. https:\/\/doi.org\/10.3390\/ijms23094485 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"91356_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115149","author":"M Miedziaszczyk","year":"2023","unstructured":"Miedziaszczyk, M. & Idasiak-Piechocka, I. Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients \u2013 A review. Biomed. Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2023.115149 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"91356_CR54","doi-asserted-by":"publisher","unstructured":"Amaro-\u00c1lvarez, L., Cordero-Ramos, J. & Calleja-Hern\u00e1ndez, M. \u00c1. Exploring the impact of pharmacogenetics on personalized medicine: A systematic review. Farmacia Hospitalaria 48, 299\u2013309, https:\/\/doi.org\/10.1016\/j.farma.2023.12.004 (2024).","DOI":"10.1016\/j.farma.2023.12.004"},{"key":"91356_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1201906","author":"LM de Jong","year":"2023","unstructured":"de Jong, L. M. et al. The impact of CYP2C19 genotype on phenoconversion by concomitant medication. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1201906 (2023).","journal-title":"Front. Pharmacol."},{"key":"91356_CR56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cld.2016.08.011","volume":"21","author":"S Ganesh","year":"2017","unstructured":"Ganesh, S. et al. Drug interactions, and Drug-Induced liver injury in living donor liver transplant patients. Clin. Liver Dis. 21, 181\u2013196. https:\/\/doi.org\/10.1016\/j.cld.2016.08.011 (2017).","journal-title":"Clin. Liver Dis."},{"key":"91356_CR57","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2478\/10004-1254-60-2009-1885","volume":"60","author":"N Bo\u017eina","year":"2009","unstructured":"Bo\u017eina, N., Bradamante, V. & Lovri\u0107, M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and Cancer risk. Archives Industrial Hygiene Toxicol. 60, 217\u2013242. https:\/\/doi.org\/10.2478\/10004-1254-60-2009-1885 (2009).","journal-title":"Archives Industrial Hygiene Toxicol."},{"key":"91356_CR58","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bcp.12086","volume":"76","author":"KM Knights","year":"2013","unstructured":"Knights, K. M., Rowland, A. & Miners, J. O. Renal drug metabolism in humans: the potential for drug\u2013endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br. J. Clin. Pharmacol. 76, 587\u2013602. https:\/\/doi.org\/10.1111\/bcp.12086 (2013).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"91356_CR59","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13318-021-00745-6","volume":"47","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Assessment of the effects of Inhibition or induction of CYP2C19 and CYP2C9 enzymes, or Inhibition of OAT3, on the pharmacokinetics of abrocitinib and its metabolites in healthy individuals. Eur. J. Drug Metab. Pharmacokinet. 47, 419\u2013429. https:\/\/doi.org\/10.1007\/s13318-021-00745-6 (2022).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"91356_CR60","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","volume":"187","author":"JS Wang","year":"2006","unstructured":"Wang, J. S., Zhu, H. J., Markowitz, J. S., Donovan, J. L. & DeVane, C. L. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology 187, 415\u2013423. https:\/\/doi.org\/10.1007\/s00213-006-0437-9 (2006).","journal-title":"Psychopharmacology"},{"key":"91356_CR61","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1177\/0091270006293753","volume":"46","author":"RL Walsky","year":"2006","unstructured":"Walsky, R. L., Astuccio, A. V. & Obach, R. S. Evaluation of 227 drugs for in vitro Inhibition of cytochrome P450 2B6. J. Clin. Pharmacol. 46, 1426\u20131438. https:\/\/doi.org\/10.1177\/0091270006293753 (2006).","journal-title":"J. Clin. Pharmacol."},{"key":"91356_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102413","author":"K Suetsugu","year":"2019","unstructured":"Suetsugu, K. et al. Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20102413 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"91356_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1292163","author":"BN Huo","year":"2024","unstructured":"Huo, B. N. et al. Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1292163 (2024).","journal-title":"Front. Pharmacol."},{"key":"91356_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20071-3","author":"JH Kim","year":"2018","unstructured":"Kim, J. H. et al. Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-018-20071-3 (2018).","journal-title":"Sci. Rep."},{"key":"91356_CR65","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bcpt.12914","volume":"122","author":"H Zhang","year":"2018","unstructured":"Zhang, H. et al. Prediction of Drug-Drug interaction between tacrolimus and principal ingredients of Wuzhi capsule in Chinese healthy volunteers using Physiologically-Based Pharmacokinetic modelling. Basic. Clin. Pharmacol. Toxicol. 122, 331\u2013340. https:\/\/doi.org\/10.1111\/bcpt.12914 (2018).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"91356_CR66","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","volume":"44","author":"T Wang","year":"2014","unstructured":"Wang, T. et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int. J. Antimicrob. Agents. 44, 436\u2013442. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.07.013 (2014).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"91356_CR67","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00228-010-0869-3","volume":"66","author":"HY Shi","year":"2010","unstructured":"Shi, H. Y. et al. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. Eur. J. Clin. Pharmacol. 66, 1131\u20131136. https:\/\/doi.org\/10.1007\/s00228-010-0869-3 (2010).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"91356_CR68","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/0091270010395510","volume":"52","author":"S Lee","year":"2012","unstructured":"Lee, S. et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J. Clin. Pharmacol. 52, 195\u2013203. https:\/\/doi.org\/10.1177\/0091270010395510 (2012).","journal-title":"J. Clin. Pharmacol."},{"key":"91356_CR69","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00228-012-1432-1","volume":"69","author":"JJ Zhang","year":"2013","unstructured":"Zhang, J. J., Zhang, H., Ding, X. L., Ma, S. & Miao, L. Y. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. Eur. J. Clin. Pharmacol. 69, 807\u2013812. https:\/\/doi.org\/10.1007\/s00228-012-1432-1 (2013).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"91356_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2021.100091","author":"Q Xu","year":"2021","unstructured":"Xu, Q. et al. Metabolism and transporter based drug\u2013drug interaction of tacrolimus with nine co-medicated injections. Med. Drug Discovery. https:\/\/doi.org\/10.1016\/j.medidd.2021.100091 (2021).","journal-title":"Med. Drug Discovery"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91356-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91356-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91356-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:25:50Z","timestamp":1740133550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91356-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91356"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91356-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study uses de-identified liver microsomes obtained from the Reed Institute for Liver Disease. The Ethics Committee of The Second Xiangya Hospital of Central South University did not require the study to be reviewed or approved by an ethics committee because the samples were industrial commodities and de-identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"6389"}}